Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
ALK-Abelló A/S |
---|---|
Information provided by: | ALK-Abelló A/S |
ClinicalTrials.gov Identifier: | NCT00293046 |
This trial is performed to assess whether the Grazax® treatment compliance can be improved by use of a compliance device (Memozax®).
Condition | Intervention | Phase |
---|---|---|
Allergy |
Biological: ALK Grass tablet - use of compliance device |
Phase III |
Study Type: | Interventional |
Study Design: | Randomized, Open Label, Active Control, Parallel Assignment |
Official Title: | A Randomised, Parallel-Group, Open, Controlled Phase III Trial Assessing the Treatment Compliance With GRAZAX® in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis |
Estimated Enrollment: | 500 |
Study Start Date: | February 2006 |
Study Completion Date: | October 2007 |
Primary Completion Date: | September 2006 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | GT-10 |
Study First Received: | February 16, 2006 |
Last Updated: | September 29, 2008 |
ClinicalTrials.gov Identifier: | NCT00293046 |
Health Authority: | Denmark: Danish Medicines Agency; Austria: Federal Ministry for Health and Women; Sweden: Medical Products Agency; Netherlands: Medicines Evaluation Board (MEB); Germany: Paul-Ehrlich-Institut |
Allergy |
Hypersensitivity |